* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Class 2
Survey
Document related concepts
Transcript
Investment Strategy April 11, 2007 (LA) or April 5, 2007 (OCC) J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 Strategic Issues raised by NPV Sources of NPV Sequencing of decisions Dealing with uncertainty Open questions – the discount rate – affecting the market value for investors J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 Sources of Present Values Michael Porter’s analysis (e.g. Competitive Strategy, 1980) – – – – – Competitors Suppliers Customers Substitutes Potential entrants No advantage lasts forever in competitive markets J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 Sequencing of Decisions Most investments can be developed in a sequence of stages where the investment strategy can be refined or the project abandoned Good result Decision trees useful Good result Expand Test Market Bad result Bad result J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 Close Down Stewart Pharmaceuticals The Stewart Pharmaceuticals Corporation is considering investing in developing a drug that cures the common cold. A corporate planning group, including representatives from production, marketing, and engineering, has recommended that the firm go ahead with the test and development phase. This preliminary phase will last one year and cost $1 billion. Furthermore, the group believes that there is a 60% chance that tests will prove successful. If the initial tests are successful, Stewart Pharmaceuticals can go ahead with full-scale production. This investment phase will cost $1.6 billion. Production will occur over the next 4 years. J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 Decision Tree for Stewart Pharmaceutical The firm has two decisions to make: To test or not to test. To invest or not to invest. Success Test Invest NPV = $3.4 b Do not invest NPV = $0 Failure Do not test NPV $0 J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 Invest NPV = –$91.46 m Stewart Pharmaceutical: Test? Let’s move back to the first stage, where the decision boils down to the simple question: should we invest? The expected payoff evaluated at date 1 is: Expected payoff Payoff Payoff Prob. Prob. sucess given success failure given failure Expected payoff .60 $3,433.75 .40 $0 $2,060.25 • The NPV evaluated at date 0 is: NPV $1,000 $2,060.25 $872.95 1.10 So we should test. J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 Dealing with Uncertainty We have implicitly been dealing with expected cash flows - each cash flow represents a probability-weighted average of likely outcomes Alternatives methods are to deal with several alternatives (scenario analysis) or to identify critical assumptions (sensitivity analysis) Break-even points may assist evaluation J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 Break-Even Analysis Accounting break-even analysis Accounting Breakeven Present-value Fixed Costs Depreciati on Gross M arg in break-even analysis EAC Fixed Costs * (1 Tc ) Depreciati on * Tc Pr esent Value Breakeven Gross M arg in * (1 Tc ) Example J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 Examples of PV vs Real Options Value of motel is costing $9.7 million expected worth $10 million at 10% yields NPV of $300,000 $10 million is expected value of two equally likely outcomes, $11 and $9 million, future will reveal information about true value of motel Management could wait one year to take advantage of this information This value of project with option to postpone is .5*($1.3)/1.1 = $ .591 million (since no bad outcome) so option value is $ .591 - $ .300 = $.291 million J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 Management options Abandon Contract Switch Wait Expand Growth Currently Invested: React to Bad News Not Currently Invested Currently Invested: React to Good News J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 Real Options and Investment Growth options – May increase size of investment later Timing options – Delay and learn more about opportunities Switching options – Change nature or use of invested assets Option to expand or contract (scale) Abandonment options J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 Open Questions How do we actually choose the discount rates? If we make positive net present value decisions, how will they affect our share price? Can the market understand every possible strategy -- should we play out a strategy even though our share price suffers? J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007 For Class 11 and Following Week Read Chapters 9 and 10 and work problems for next week Work on Part 3 of group project (due April 25 (LA) or April 24 (OCC)) and identify any questions or problems requiring assistance from instructor Read handout on Sheet 2 “Continuing Values” assumptions for PVFIRM05 J. K. Dietrich - GSBA 548 – MBA.PM Spring 2007